Navigation Links
The Lancet Publishes Data from Protege, MacroGenics' Phase 3 Clinical Study of Teplizumab in Type 1 Diabetes Patients
Date:6/28/2011

ROCKVILLE, Md., June 28, 2011 /PRNewswire/ -- MacroGenics, Inc., a privately held biotechnology company that develops immunotherapeutics to treat autoimmune disorders, cancer and infectious diseases, announced the publication in The Lancet of results from Protege, a Phase 3 clinical study of teplizumab in type 1 diabetes.  Exploratory, post-hoc analyses suggest that teplizumab, an anti-CD3 monoclonal antibody, when used in a 14-day full dose regimen, preserves C-peptide and increases the percentage of patients requiring very low doses of insulin (< 0.25 U/kg/day) with good glycemic control (glycosylated hemoglobin, or HbA1C < 7%) compared to placebo.  In addition, these analyses revealed that certain subpopulations may be more likely to respond to teplizumab treatment.  These findings also were presented today by Dr. Nicole Sherry (Massachusetts General Hospital for Children) at the annual American Diabetes Association meeting.

Protege is a two-year, randomized, double-blind, placebo-controlled clinical trial, with 513 patients aged 8–35, recently diagnosed with type 1 diabetes, who were enrolled and treated at 83 clinical centers in North America, Europe, Israel, and India. Participants were allocated 2:1:1:1 to receive daily infusions of teplizumab (full dose for 14 days, 1/3 dose for 14 days, or full dose for 6 days) or placebo at baseline and at 6 months. The primary composite endpoint of the Protege study was the percentage of patients with insulin use < 0.5 U/kg/day and HbA1C < 6.5% at 1 year.  Although teplizumab was shown to have an acceptable safety profile, the primary endpoint was not achieved, as had been previously announced in a joint communication with Eli Lilly and Company in October 2010.  Protege is ongoing and will complete the 2-year follow-up in 2011.

The peer-reviewed article appearing in The Lancet is titled, "Teplizumab for treatment of type 1 diabetes (Protege study):
'/>"/>

SOURCE MacroGenics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Final Published Trial Data in The Lancet Supports Safety and Effectiveness of MicroVention-Terumos HydroCoil® Embolic System for Treatment of Cerebral Aneurysms
2. QNEXA® Phase 3 Data in The Lancet Show Significant Weight Loss and Broad Improvements in Co-Morbidities
3. Results Published in The Lancet Demonstrate Superiority of XGEVA™ (Denosumab) in the Prevention of Bone Complications for Men With Bone Metastases From Advanced Prostate Cancer
4. CHAMPION Study Published in The Lancet
5. Phase III Data Published in Lancet Show Novartis Drug Zometa® Improves Overall Survival in Newly Diagnosed Multiple Myeloma Patients
6. Phase III Data Showing Improved Survival With Jevtana® (cabazitaxel) Injection in Second-Line Advanced Prostate Cancer Published in The Lancet
7. Data Published in The Lancet Compare Dabigatran Etexilate to Dose-Adjusted Warfarin Across RE-LY® Trial Centers
8. Orexigen® Therapeutics Announces Publication of COR-I Phase 3 Study of Contrave in Lancet
9. Boehringer Ingelheim Affirms Safety of Telmisartan With an Analysis of 50,000 Patients and Strongly Disagrees With the Publication of Sipahi et al in Lancet Oncology June 2010
10. The Lancet publishes new data demonstrating superior efficacy of Victoza(R) (liraglutide [rDNA] injection) compared to Januvia(R) (sitagliptin) in the treatment of type 2 diabetes
11. Landmark Study in The Lancet Oncology Shows Capecitabine (Xeloda(R)) Combination Therapy Reduces Early Breast Cancer Recurrence
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)...  The U.S. Department of Health and Human Services ... (UH) Case Medical Center Seidman Cancer Center totaling $4.7 ... improving care for patients with complex cancer. ... a unique model developed at UH to enhance care ... or demonstrated need for high health care utilization.  ...
(Date:7/10/2014)... 10, 2014  RESMED INC. (NYSE: RMD ) ... fiscal year ended June 30, 2014 results on Thursday, July ... A press release with ResMed,s results will be issued after ... a webcast to discuss operating results and future outlook. ... p.m. US Pacific Time and the live webcast of the ...
(Date:7/10/2014)... 10, 2014  Valeant Pharmaceuticals International, Inc. (NYSE: ... has completed the sale to Galderma of all rights ... held by Valeant for $1.4 billion in cash, pursuant ... recently completed its acquisition of Galderma. ... products to a company that is firmly committed to ...
Breaking Medicine Technology:University Hospitals Case Medical Center Awarded $4.7 Million Grant from U.S. Department of Health and Human Services 2University Hospitals Case Medical Center Awarded $4.7 Million Grant from U.S. Department of Health and Human Services 3University Hospitals Case Medical Center Awarded $4.7 Million Grant from U.S. Department of Health and Human Services 4ResMed To Announce Fourth Quarter And Fiscal Year-End 2014 Results 2
(Date:7/12/2014)... July 12, 2014 Tylenol lawsuits ... to move forward in the federal multidistrict litigation ... Pennsylvania, Bernstein Liebhard LLP reports. According to a ... Lawrence F. Stengel has ordered the deposition of ... Stengel found that the witness’s testimony concerning the ...
(Date:7/12/2014)... "The second toes cross over the big ... wear shoes," said an inventor from East Hartford, Conn. This ... from happening. , He then created a prototype of the ... second and big toes from overlapping. This avoids discomfort and ... and easy to use, it's ideal for people with foot ...
(Date:7/12/2014)... (PRWEB) July 12, 2014 As DePuy ... forward in U.S. courts, Bernstein Liebhard LLP notes the ... ion levels to the failure of metal-on-metal hip replacements. ... of The Journal of Bone & Joint Surgery, looked ... Articular Surface Replacement prostheses at least twelve months earlier. ...
(Date:7/12/2014)... July 12, 2014 “Critical Care ... New and Late-Stage Four-Factor PCCs and Recombinant Products ... the critical care market in the US, UK, ... report provides an estimation of market size for ... covers critical care indications that are being treated ...
(Date:7/12/2014)... Emirates (PRWEB) July 12, 2014 Dubai ... Angeles basketball legend is heading to the UAE. ... six-time champion will be in the UAE from 28-31 ... Weekend in support of diabetes awareness. The event is ... entertainment marketing and event management company based in Dubai. ...
Breaking Medicine News(10 mins):Health News:Tylenol Lawsuit News: U.S. District Judge Overseeing Federal Tylenol Liver Damage Litigation Orders Deposition of Former McNeil President, Bernstein Liebhard LLP Reports 2Health News:Tylenol Lawsuit News: U.S. District Judge Overseeing Federal Tylenol Liver Damage Litigation Orders Deposition of Former McNeil President, Bernstein Liebhard LLP Reports 3Health News:Tylenol Lawsuit News: U.S. District Judge Overseeing Federal Tylenol Liver Damage Litigation Orders Deposition of Former McNeil President, Bernstein Liebhard LLP Reports 4Health News:DePuy Pinnacle Hip Lawsuit News: Bernstein Liebhard LLP Notes Release of New Study Tying Elevated Metal Ions to Metal-on-Metal Hip Failure 2Health News:DePuy Pinnacle Hip Lawsuit News: Bernstein Liebhard LLP Notes Release of New Study Tying Elevated Metal Ions to Metal-on-Metal Hip Failure 3Health News:DePuy Pinnacle Hip Lawsuit News: Bernstein Liebhard LLP Notes Release of New Study Tying Elevated Metal Ions to Metal-on-Metal Hip Failure 4Health News:Critical Care Therapeutics in Major Developed Market is Expected to Grow at a CAGR of 4.7% to $2.5 Billion in 2019 2Health News:Critical Care Therapeutics in Major Developed Market is Expected to Grow at a CAGR of 4.7% to $2.5 Billion in 2019 3Health News:Critical Care Therapeutics in Major Developed Market is Expected to Grow at a CAGR of 4.7% to $2.5 Billion in 2019 4Health News:Critical Care Therapeutics in Major Developed Market is Expected to Grow at a CAGR of 4.7% to $2.5 Billion in 2019 5Health News:Critical Care Therapeutics in Major Developed Market is Expected to Grow at a CAGR of 4.7% to $2.5 Billion in 2019 6Health News:Los Angeles Basketball Legend Headed to Dubai 2Health News:Los Angeles Basketball Legend Headed to Dubai 3
... Just another AccessorySCARBOROUGH, N.Y., March 4 No hair? ... ( BaldGirlsDoLunch.org ) brings women with alopecia areata ... heads will turn. That delights founder Thea Chassin ... hair normally. It,s time for everyone to understand it ...
... logged on to www.WorldMedAssist.com to help him find the surgeon in ... of ICU with his mitral valve replacement overseas completed. He,s now home ... ... -- When Henry Konczak first learned that his chronic fatigue was due to ...
... its advanced mobile health screening services to the ... and techniques in the industry, HealthYes! screens its clients for ... peripheral artery disease and osteoporosis. , ... ...
... detect and measure pneumothoraces in trauma patients helps physicians ... room settings, according to a study performed at Massachusetts ... , "With the rapid development of ... trauma patients replaced traditional x-ray radiography in emergency care ...
... the Journal of Clinical Endocrinology & Metabolism , ... of clinical medicine and director of the Diabetes Clinical ... with age. An estimated 37 million Americans over the ... population. Another 20 to 30 percent of seniors, an ...
... Healthcare Sustainability for America,s Hospitals and Medical ... Healthcare Waste and Emergency Preparedness Coalition (CleanMedWaste.org) ... provide education about two major problems facing ... operational sustainability during a crisis and the ...
Cached Medicine News:Health News:Seattle's First Bald Girls Do Lunch(R) 2Health News:Seattle's First Bald Girls Do Lunch(R) 3Health News:Ohio Patient Thanks India and WorldMed Assist For Heart Surgery Overseas; His Indian Surgeon Thanks U.S. for Superb Training 2Health News:Ohio Patient Thanks India and WorldMed Assist For Heart Surgery Overseas; His Indian Surgeon Thanks U.S. for Superb Training 3Health News:HealthYes! Now Offering its Preventive Health Screening Services in Houston 2Health News:HealthYes! Now Offering its Preventive Health Screening Services in Houston 3Health News:Computer-aided system effectively detects and measures pneumothoraces in chest trauma patients 2Health News:'Pre-diabetics' face heightened risk of heart disease 2Health News:The Healthcare Waste and Emergency Preparedness Coalition Announces Its Official Formation 2
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: